Program Monday Sept 4 th, Tuesday Sept 5 th

40 th Annual Scientific meeting of the European Lipoprotein Club 4-7 September 2017 PRELIMINARY PROGRAMME

40 th Annual Scientific meeting of the European Lipoprotein Club 4-7 September 2017 PRELIMINARY PROGRAMME Monday afternoon, September 4 th 14.00-16.00 Organizing Committee meeting 16.00-18.00 Arrival and

Sunday, March 22, 2015

SCIENTIFIC PROGRAMME (As of October 7, 2014) Sunday, March 22, 2015 12:00-13:30 Educational Symposium - Supported Session 12:00-13:30 Educational Symposium - Supported Session Hall B 13:30-14:00 Break

University of Parma - Karolinska Institutet IV Workshop on Lipid Metabolism and Vascular Biology

University of Parma - Karolinska Institutet IV Workshop on Lipid Metabolism and Vascular Biology Parma, Centro S. Elisabetta Campus Universitario 8-10 October, 2018 Organized by Franco Bernini (University

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

Summary and concluding remarks

Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated

Finnish Atherosclerosis Society Suomen Ateroskleroosiyhdistys ry

19.2.2017 program Finnish Atherosclerosis Society Suomen Ateroskleroosiyhdistys ry Time: Friday 17.3.2017 Photograph by Hannu Uusitalo Place: The lecture hall of the Department of Pharmacology F202, Door

Niacin Metabolism: Effects on Cholesterol

Niacin Metabolism: Effects on Cholesterol By Julianne R. Edwards For Dr. William R. Proulx, PhD, RD Associate Professor of Nutrition and Dietetics In partial fulfillments for the requirements of NUTR342

Lipid Metabolism in Familial Hypercholesterolemia

Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

Nature Genetics: doi: /ng.3561

Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8

Glossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein

EAS Congress Innsbruck Highlights: A programme to excite, inspire and inform!

Press release 84 th European Atherosclerosis Society Congress, Innsbruck, Austria For circulation 29 th May, 2016. 84 th Annual Congress of the European Atherosclerosis Society (EAS) May 29 th - June 1

Lipid metabolism in familial hypercholesterolemia

Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis

Saturday, 8 September 2018 Treatment options and update on statin treatment Chair: M. Kayikcioglu, V. Kotsis How far should we lower LDL?

Friday, 7 September 2018 11.00-11.45 Registrations 11.45-12.00 Introduction - Welcome Messages L. Tokgozoglu, V. Kotsis Atherosclerosis and cardiovascular risk update Chair: A. Tselepis, H. Kultursay 12.00-12.30

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis Mato Nagel, Ioan Duma, Constantina Vlad, Mandy Benke, Sylvia Nagorka Zentrum für Nephrologie & Stoffwechsel,

Central role of apociii

University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,

Chapter VIII: Dr. Sameh Sarray Hlaoui

Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd. Beaufort, SC 20097 Copyright Pending 2017 All rights reserved,

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

High density lipoprotein metabolism

High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC

Invited Journal: Nature Medicine. Sponsors: Thermo Fisher Novocure Merck. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain

CNIO Frontiers Meetings Primary and Secondary Brain Tumors 19th-22nd February 2017 Organisers: Richard Gilbertson CRUK Cambridge Institute, UK Michael Weller University Hospital Zurich, Switzerland Massimo

CNIO- la Caixa Foundation Frontiers Meeting- 2nd-4th MAY 2017 MOLECULAR CHAPERONES IN CANCER

Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain Chairpersons and organizing committee: Nabil Djouder, Spanish National Cancer Research Centre, Madrid, Spain Wilhelm Krek, Institute

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global

Molecular Mechanisms of Intestinal Lipid Transport and Metabolism. July 6-11, 2014 Base Village Conference Center Snowmass, CO

Molecular Mechanisms of Intestinal Lipid Transport and Metabolism July 6-11, 2014 Base Village Conference Center Snowmass, CO Co-Organizers: Dennis Black, MD (Chair) University of Tennessee Health Science

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

Cholesterol metabolism Function Biosynthesis Transport in the organism Hypercholesterolemia - component of all cell membranes - precursor of bile acids steroid hormones vitamin D Cholesterol Sources: dietary

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:

HDL : A Treatment Target? ESC Paris M. John Chapman Ph.D., D.Sc., FESC. President, European Atherosclerosis Society

ESC Paris 2011 HDL : A Treatment Target? M. John Chapman Ph.D., D.Sc., FESC Director, Dyslipidemia and Atherosclerosis Research Unit, INSERM, University Pierre and Marie Curie, Hôpital de la Pitié-Salpetriere,

FEBS 2019 Advanced Lecture Course. Biological Surfaces and Interfaces: The Mechanistic View.

FEBS 2019 Advanced Lecture Course Biological Surfaces and Interfaces: The Mechanistic View. June 30 July 5, 2019 Hotel Eden Roc Sant Feliu de Guixols, Spain Preliminary Program Chair Marta Bally Umeå University

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. Brian A. Ference MD, MPhil, MSc, John J. P. Kastelein

Arteriosclerosis & Atherosclerosis

Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)

Glossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"

Lipoproteins Metabolism

Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical

Second announcement. In addition, a pre-conference workshop on Lipidomics for biomarker and clinical analysis will take place during July 1-3, 2014.

Second announcement International conference: Healthcare integrated biobanking and multiomics biomarker analysis (July 3-5, 2014) Workshop: Lipidomics for biomarker and clinical analysis (July 1-3, 2014)

Regulating Hepatic Cellular Cholesterol

Under circumstances of cholesterol deficiency, Sterol Regulatory Element Binding Proteins (SREBPs) via binding to DNA nuclear response elements set off genomic production of proteins and enzymes that induce

2018 Kern Lipid Conference

2018 Kern Lipid Conference Metabolic Regulation of Immunity, Cardiometabolic Diseases and Cancer: New Therapeutic Approaches Monday, August 13, 2018 to Wednesday, August 15, 2018 - Vail, Colorado Organizers:

2.5. AMPK activity

Supplement Fig. A 3 B phos-ampk 2.5 * Control AICAR AMPK AMPK activity (Absorbance at 45 nm) 2.5.5 Control AICAR Supplement Fig. Effects of AICAR on AMPK activation in macrophages. J774. macrophages were

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research

Atherosclerosis Mechanisms and novel therapeutic targets International Symposium

Atherosclerosis Mechanisms and novel therapeutic targets International Symposium October 5-6, 2016 Carl Friedrich von Siemens Foundation Nymphenburg Palace, Munich Generously supported by: Wednesday, 05.10.2016

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

PCSK9 Inhibition: From Genetics to Patients

PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research

Drug Class Prior Authorization Criteria PCSK9 Inhibitors

Drug Class Prior Authorization Criteria PCSK9 Inhibitors Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of

4 th European Stroke Science Workshop

4 th European Stroke Science Workshop P R O G R A M M E 16 18 November 2017 Garmisch Partenkirchen, Germany Hotel Eibsee Final Programme 4 th ESO Stroke Science Workshop / November 16 18, 2017 Garmisch-Partenkirchen,

Food, Microbiota and Immunity "For strong immunity - feed your microbiota well" June 7-10, 2017, Castle Třešť, Czech Republic

Food, Microbiota and Immunity "For strong immunity - feed your microbiota well" June 7-10, 2017, Castle Třešť, Czech Republic Program: Wednesday June 7 14:00 Departure from Prague by bus: station metro

About OMICS International Conferences

About OMICS Group OMICS Group is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information

LLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.

ESPEN Congress Leipzig 2013 LLL Session - Nutrition support in diabetes and dyslipidemia Dyslipidemia: targeting the management of cardiovascular risk factors M. Leon Sanz (ES) Dyslipidemia: Targeting

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk

Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

6 th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the December 2014

The Cardiovascular Medicine Journal, 2015, 9, 73-77 73 Open Access 6 th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the 04-06 December 2014 Novel Pharmacologic Treatments of

Metabolism and Atherogenic Properties of LDL

Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and

Inspired Functional Ingredients to Innovate and Differentiate Your Brand. Products by Ecovatec Solutions Inc.

Inspired Functional Ingredients to Innovate and Differentiate Your Brand Products by Ecovatec Solutions Inc. High Density Lipopeptides (HDL p ) High Density Lipopeptides (HDL p ) High density lipoproteins

PPAR history of research

PPAR Rubens, 1640 PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year liver, brown adipocytes, kidney, heart, skeletal muscles,

G. Chinetti-Gbaguidi and B. Staels, UR 545 INSERM, Institut Pasteur de Lille and Université de Lille 2, Lille, France

LIVER X RECEPTORS (LXRS): TRANSCRIPTIONAL REGULATORS OF MACROPHAGE CHOLESTEROL METABOLISM G. Chinetti-Gbaguidi and B. Staels, UR 545 INSERM, Institut Pasteur de Lille and Université de Lille 2, Lille,

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism

Lipid Lowering in Patients at High Risk for Cardiovascular Disease

Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel

B. Patient has not reached the percentage reduction goal with statin therapy

Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

International Hepatitis Symposium Heidelberg

16 th May 18 th May 2018 International Hepatitis Symposium Heidelberg Ralf Bartenschlager s 60 th Birthday Symposium (16 th ) AND International Symposium of the TRR179 (17 th to 18 th ) Confirmed Speakers:

FEBS ADVANCED LECTURE COURSE

FEBS ADVANCED LECTURE COURSE SUNDAY, August 25 From 16.00 Registration 19.15 - Opening remarks (organizers) 19.30 Self-presentation of all participants 21.00 Welcome reception MONDAY, August 26 Karen Knudsen,

Familial hypercholesterolaemia in children and adolescents

Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:

LYON. FRANCE NOVEMBER / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE AND CLINICAL RESEARCH

LYON. FRANCE NOVEMBER 29-30 / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE https://events.easl.eu/eventportal/ Information/MLYON2013/HOME.aspx Abstract submission deadline:

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins

Review Article Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins A. R. Tall From the Division of Molecular Medicine, Department

Lipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel

Lipid Metabolism Department of Biochemistry and Molecular Biology II Medical Center Hamburg-ppendorf 1 Lipids. visceral fat. nutritional lipids 0 1.5 3 4.5 9 h. serum lipids. lipid accumulation in the

INTERNATIONAL SYMPOSIUM ON MEDICATION RELATED OSTEONECROSIS OF THE JAWS (MRONJ)

INTERNATIONAL SYMPOSIUM ON MEDICATION RELATED OSTEONECROSIS OF THE JAWS (MRONJ) TO BE HELD IN COPENHAGEN, DENMARK 29 th of September 2017 FOR FURTHER INFORMATION: Link to come INTRODUCTION Medication Related

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown

Lipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?

Lipids Board Review Ira Goldberg, MD New York University School of Medicine 1. A 22 year old male college student is referred for severe hypertriglyceridemia ( 1500 mg/dl [ 17.0 mmol/l]). He has a history

Cellular control of cholesterol. Peter Takizawa Department of Cell Biology

Cellular control of cholesterol Peter Takizawa Department of Cell Biology Brief overview of cholesterol s biological role Regulation of cholesterol synthesis Dietary and cellular uptake of cholesterol

Familial Hypercholesterolemia

Familial Hypercholesterolemia Dr.Ramzi Al-Mohammadi Assistant Professor of Medicine Interventional Cardiologist, Advanced HF and Transplant Consultant Classification of Hyperlipedemia Primary hyperlipedemia:

Fourth Symposium on Phospholipids in Pharmaceutical Research. 21 st 22 nd, September 2015 Heidelberg, Germany. 3rd Circular

Fourth Symposium on Phospholipids in Pharmaceutical Research 21 st 22 nd, September 2015 Heidelberg, Germany 3rd Circular page 2 Introduction Phospholipids excipients are worldwide being used in many registered

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density

PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL

PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL Lipids are characterized by low polarity and limited solubility in water. Their plasma concentration is about 500-600

Cholesterol, Heart Attack and Stroke. Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital

Cholesterol, Heart Attack and Stroke Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital Outline Why are we interested in cholesterol What is a heart attack and how does it

Lipoprotein Particle Profile

Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

Is it really that simple? Alyssa Hasty, PhD Associate Professor Molecular Physiology and Biophysics

Alyssa Hasty, PhD Associate Professor Molecular Physiology and Biophysics Why we care about hepatic lipogenesis Control of lipid synthesis What can go wrong in humans Animal models dlto study lipoprotein

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy

Acetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol

Low HDL-levels: leave it or treat it?

Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960

Clinical Cytogenetics September 14 th 20 th, 2014 Goldrain, South Tyrol, Italy

Thanks for their support to: E.C.A. European Cytogeneticists Association Clinical Cytogenetics September 14 th 20 th, 2014 Goldrain, South Tyrol, Italy DIRECTOR: A. Schinzel (Zurich, Switzerland) FACULTY:

Dr G R Letchuman. Clogged by Cholesterol

Dr G R Letchuman Clogged by Cholesterol Main message Cholesterol management is all about reducing risk of CV events vs the side effects, hassle and cost of drugs News that it is no longer important to

MORNING MID MORNING MIDDAY AFTERNOON EVENING. HEART UK Committee Meetings

Hot Topics in Atherosclerosis and Cardiovascular Disease 32nd Annual Medical & Scientific Conference 2018: CONFERENCE PROGRAMME PROGRAMME SUMMARY: MORNING MID MORNING MIDDAY AFTERNOON EVENING WED Hyperlipidaemia

Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome. James Kyle Taylor

Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome by James Kyle Taylor A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of

Metabolic defects underlying dyslipidemia in abdominal obesity

Metabolic defects underlying dyslipidemia in abdominal obesity Professor Marja-Riitta Taskinen Department of Medicine, Division of Cardiology Helsinki University Hospital, Finland Disclosures: Honorariums/

Lipids digestion and absorption, Biochemistry II

Lipids digestion and absorption, blood plasma lipids, lipoproteins Biochemistry II Lecture 1 2008 (J.S.) Triacylglycerols (as well as free fatty acids and both free and esterified cholesterol) are very

Zuhier Awan, MD, PhD, FRCPC

Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier

DIABETES AND MACROVASCULAR DISEASE

Second International Course on DIABETES AND MACROVASCULAR DISEASE Lugano (CH), March 27-29, 2003 Scientific Programme Thursday, March 27, 2003 15.45 16.00 Opening Remarks Session 1: DIABETES MELLITUS A

PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019

PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019 Professor Gilles Lambert, PhD LaboratoireInserm U1188 Universitéde la Réunion Faculté de Médecine Saint Denis de la Réunion,

Immunological Aspects of Metabolic Syndrome

Immunological Aspects of Metabolic Syndrome August 12-17, 2018 Base Village Conference Center, Snowmass, CO Co-Organizers Suneil Koliwad, MD, PhD UCSF Julie Jameson, PhD CSU San Marcos Dongsheng Cai, MD,

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

Saturday, 11th February 2017

Friday, 10th February 2017 Opening Lecture Chairpersons: Karam Kostner and David Colquhoun Lipid Lowering Therapy: Exciting New Developments and Challenges 18:00-19:00 Peter Toth, University of Illinois

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients

VENUE. NMI Natural and Medical Sciences Institute at the University of Tübingen. Markwiesenstrasse 55, Reutlingen, Germany

VENUE NMI Natural and Medical Sciences Institute at the University of Tübingen Markwiesenstrasse 55, 72770 Reutlingen, Germany GPS-Coordinate: 48 29 38.24 N 9 08 02.73 O AGENDA Get updated about latest